In:
Pharmacia, Pensoft Publishers, Vol. 69, No. 3 ( 2022-07-08), p. 631-636
Abstract:
Chlorambucil (CBL) is an efficient anticancer drug. It is a lipophilic agent with serious adverse effects. The objective of this study was to formulate a CBL-loaded nanolipid carrier and target breast cancer using folic acid as a targeting probe. Characterizations of the optimum formulation were 79.9±3% EE after the addition of 4mg CBL, 119±6nm particle size which is considered appropriate for parenteral use, 0.3±0.02 PDI, -42±1mV ZP that stabilized the formulation. Tumor volume, body weight, and tumor mass weight were recorded to evaluate tumor volume doubling time, tumor growth inhibition rate, and systemic toxicity. It appeared there was a significant antitumor activity of targeted formulation compared with non-targeted one and free CBL. Moreover, the systemic toxicity was less after body weight evaluation concerning the targeted formulation when compared with other formulations.
Type of Medium:
Online Resource
ISSN:
2603-557X
,
0428-0296
DOI:
10.3897/pharmacia.69.e85390
DOI:
10.3897/pharmacia.69.e85390.figure1
DOI:
10.3897/pharmacia.69.e85390.figure2
DOI:
10.3897/pharmacia.69.e85390.figure3
DOI:
10.3897/pharmacia.69.e85390.figure4
Language:
Unknown
Publisher:
Pensoft Publishers
Publication Date:
2022
detail.hit.zdb_id:
3010005-7
SSG:
15,3